

AMENDMENTS

IN THE SPECIFICATION:

Please replace the specification with the enclosed substitute specification.

IN THE CLAIMS:

Please cancel original claims 12-14.

Please amend the claims as follows:

1. (amended) A method for inhibiting angiogenesis in a mammal in need thereof comprising administering to the mammal a monoclonal antibody or antigen-binding fragment thereof which acts as an antagonist of the integrins GPIIb/IIIa($\alpha_{IIb}\beta_3$) and $\alpha_v\beta_3$ in an amount effective to inhibit angiogenesis in said mammal.
2. (amended) The method according to claim 1, in which the antigen-binding fragment is an Fab, Fab', or F(ab')2 fragment or derivative thereof.
3. (amended) The method according to claim 1, in which the monoclonal antibody is selected from the group consisting of monoclonal antibody 7E3, produced by the ATCC 8832 hybridoma cell line and a murine/human chimeric monoclonal antibody or antigen-binding fragment thereof comprising the Fab region of monoclonal antibody 7E3.